Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight

Psychopharmacology

Volumn 149, Issue 2, 2000, Pages 163-169

  Hinze Selch, Dunja ^a   Deuschle, Michael ^b   Weber, Bettina ^b   Heuser, Isabella ^b   Pollmächer, Thomas ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Clozapine; Cytokines; Fluvoxamine; Metabolism; Side effect; White blood cell counts

Indexed keywords

CLOZAPINE; CYTOKINE; CYTOKINE RECEPTOR; FLUVOXAMINE; LEPTIN; NORCLOZAPINE; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD CELL; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SCHIZOPHRENIA;

EID: 0034007423     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002139900351     Document Type: Article

References (38)

1. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. N Engl J Med 329:162-167
2. Alvir JMJ, Lieberman JA, Safferman AZ (1995) Do white-cell count spikes predict agranulocytosis in clozapine recipients? Psychopharmacol Bull 31:311-314
3. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders, 3rd edn. American Psychiatric Press, Washington, D.C.
4. Angst J, Bente D, Berner P, Heimann H, Helmchen H, Hippius H (1971) Das klinische Wirkungsbild von Clozapin (Untersuchungen mit dem AMP-System). Pharmacopsychiatrie 13: 201-211
5. Argiles JM, Lopez-Soriano J, Busquets S, Lopez-Soriano FJ (1997) Journey from cachexia to obesity by TNF. FASEB 11:743-751
6. Auwerx J, Staels B (1998) Leptin. Lancet 351:737-742
7. Baldessarini RJ, Frankenburg FR (1991) Clozapine - a novel antipsychotic agent. N Engl J Med 324:746-754
8. Blum A, Mauruschat W (1972) Temperaturanstiege und Bluteiweißveränderungen unter der Therapie mit Neuroleptika -unter besonderer Berücksichtigung des neuartigen Dibenzodiazepin-Derivats Clozapin. Pharmacopsychiatrie 5:155-169
9. Brömel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg JC, Hebebrand (1998) Serum leptin levels increase rapidly after initiation of clozapine treatment. Mol Psychiatry 3:76-80
10. Frieboes RM, Murck H, Antonijevic I, Kraus T, Hinze-Selch D, Pollmächer T, Steiger A (1999) Characterization of the sigma ligand panamesine, a potential antipsychotic, by immune response in patients with schizophrenia and by sleep-EEG changes in normal controls. Psychopharmacology 141:107-110
11. Guitton C, Abbar M, Konowski JM, Chabrand P, Bressolle F (1998) Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 18:470-476
12. Guitton C, Kinowski JM, Abbar M, Chabrand P, Bressolle F (1999) Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J Clin Pharmacol 39:721-728
13. Haring C, Meise U, Kumpel C, Saria A, Fleischhaker WW, Hinterhuber H (1989) Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology 99:S38-S40
14. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279-281
15. Hinze-Selch D, Mullington J, Pollmächer T (1995) Sleep during clozapine-induced fever in a schizophrenic patient. Biol Psychiatry 38:690-693
16. Hinze-Selch D, Mullington J, Orth A, Lauer CJ, Pollmächer T (1997) Effects of clozapine on sleep: a longitudinal study. Biol Psychiatry 42:260-266
17. Hinze-Selch D, Becker EW, Stein GM, Berg PA, Mullington J, Holsboer F, Pollmächer T (1998) Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 19: 114-122
18. Hummer M, Kurz M, Barnas C, Saria A, Fleischhacker WW (1994) Clozapine-induced white blood count disorders. J Clin Psychiatry 55:429-432
19. Jones-Brando LV, Buthod JL, Holland LE, Yolken RH, Torrey EF (1997) Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1. Schizophr Res 25:63-70
20. Kraus T, Haack M, Schuld A, Hinze-Selch D, Kühn M, Uhr M, Pollmächer T (1999) Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 156:312-314
21. Krueger JM, Fang J, Taishi P, Chen Z, Kushikata T, Gardi J (1998) Sleep: a physiologic role for IL-1 beta and TNF-alpha. Ann N Y Acad Sci 856:148-59
22. Lammers CH, Deuschle M, Weigmann H, Härtter S, Hiemke C, Heese C, Heuser I (1999) Coadministration of clozapine and fluvoxamine in psychotic patients - clinical experiences. Pharmacopsychiatry 32:76-77
23. Maes M, Meltzer HY, Bosmans E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89:346-351
24. Maggs JL, Williams D, Pirmohamed M, Park BK (1995) The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J Pharmacol Exp Ther 275:1463-1475
25. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK (1995) Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272:984-990
26. 51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism. J Clin Psychiatry 55:143-148
27. Pollmächer T, Mullington J, Korth C, Hinze-Selch D (1995) Influence of host defense activation on sleep in humans. Adv Neuroimmunol 5:155-169
28. Pollmächer T, Hinze-Selch D, Mullington J (1996) Effects of clozapine on cytokines and soluble cytokine receptors. J Clin Psychopharmacol 16:403-409
29. Pollmächer T, Fenzel T, Mullington J, Hinze-Selch D (1997) The influence of clozapine treatment on plasma granulocyte colony-stimulating factor (G-CSF) levels. Pharmacopsychiatry 30: 118-121
30. Schuld A, Kraus T, Haack, M, Hinze-Selch D, Kühn M, Pollmächer T (2000) Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine. Schizophr Res (in press)
31. Shader RI, Greenblatt DJ (1998) Clozapine and fluvoxamine, a curious complexity. J Clin Psychopharmacol 18:101-102
32. Silver H, Shmugliakov N (1998) Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double blind study. J Clin Psychopharmacol 18: 208-211
33. Szegedi A, Wiesner J, Hiemke C (1995) Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 15:141-142
34. Szegedi A, Anghelescu I, Wiesner J, Schlegel S, Weigmann H, Hartter S, Hiemke C, Wetzel H (1999) Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32:148-153
35. Tschen AC, Rieder MJ, Oyewumi LK, Freeman DJ (1999) The cytotoxicity of clozapine metabolites: implications for predicting clozapine-induced agranulocytosis. Clin Pharmacol Ther 65: 526-532
36. Uetrecht JP (1990) Metabolism of clozapine by neutrophils. Drug Saf 7:51-56
37. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Härtter S, Hiemke C (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18:2-9
38. Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JL, Park BK (1997) Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 283:1375-1382